Asset Details
Do you wish to reserve the book?
The opportunity cost of androgen suppression in locally advanced prostate cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The opportunity cost of androgen suppression in locally advanced prostate cancer
Do you wish to request the book?
The opportunity cost of androgen suppression in locally advanced prostate cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The opportunity cost of androgen suppression in locally advanced prostate cancer
2013
Overview
The use of androgen suppression ther- apy （AST） and radiotherapy for locallyadvanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk for side effects. Recently, Denham and colleagues have reported ini- tial quality of life （QoL） results from the TROG 03.04 RADAR trial. The authors identify clinically meaningful decrements in patient-reported QoL for those treated with 18 months of AST vs. 6 months but only marginal differences at 36 months. Once survival data becomes available, these data will help to frame any benefits seen for longer courses of AST.
Publisher
Medknow Publications & Media Pvt. Ltd,Nature Publishing Group
Subject
/ Androgen Antagonists - therapeutic use
/ Antineoplastic Agents, Hormonal - therapeutic use
/ AST
/ Bone Density Conservation Agents - therapeutic use
/ Diphosphonates - therapeutic use
/ Humans
/ Imidazoles - therapeutic use
/ Leuprolide - therapeutic use
/ Male
/ Prostatic Neoplasms - therapy
/ 前列腺癌
/ 副作用
/ 晚期
/ 机会成本
/ 治疗
/ 生活质量
/ 雄激素
